0001193805-18-001175.txt : 20181001 0001193805-18-001175.hdr.sgml : 20181001 20181001093411 ACCESSION NUMBER: 0001193805-18-001175 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20181001 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20181001 DATE AS OF CHANGE: 20181001 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 181096076 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 8-K 1 e617962_8k-adma.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 1, 2018

 

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)
     
Delaware 001-36728 56-2590442

(State or other jurisdiction

of incorporation)

(Commission

File Number) 

(IRS Employer 

Identification No.)

   
465 State Route 17, Ramsey, New Jersey 07446
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (201) 478-5552

 

 
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ý

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

Item 8.01 Other Events.

  

On October 1, 2018, ADMA Biologics, Inc., a Delaware corporation (the “Company”), issued a press release announcing that the Company has responded to the July 2016 Complete Response Letter and resubmitted its Biologics License Application for its product candidate, RI-002, to the U.S. Food and Drug Administration on September 28, 2018.

 

The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. Description
   
99.1 ADMA Biologics, Inc. Press Release, dated October 1, 2018.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

October 1, 2018 ADMA Biologics, Inc.
   
   
  By: /s/ Brian Lenz
    Name: Brian Lenz
    Title: Executive Vice President and Chief Financial Officer

EX-99.1 2 e617962_ex99-1.htm

 

 

 

ADMA Biologics Resubmits Biologics License Application for RI-002

 

RAMSEY, NJ & BOCA RATON, FL– October 1, 2018 – ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease (“PIDD”) and the prevention and treatment of certain infectious diseases, announces that the Company has responded to the July 2016 Complete Response Letter (“CRL”) and resubmitted its Biologics License Application (“BLA”) for RI-002 its product candidate to the U.S. Food and Drug Administration (“FDA”) on September 28, 2018.

 

The Company was able to resubmit RI-002’s BLA as a direct result of the recent improvement in compliance status for the Company’s Boca Raton, FL manufacturing facility to Voluntary Action Indicated (“VAI”), as previously announced in September 2018.

 

“We are pleased that our remediation efforts have been successful and we are now operating our biologics production facility in accordance with the FDA’s quality and compliance expectations. Because of the hard work of our dedicated and talented staff, ADMA is now in a position to submit applications to FDA for substantive review and approval including our BLA for RI-002, our lead pipeline-product candidate. We have been informed by FDA that the Company should no longer receive CRL’s solely for compliance reasons,” stated Adam Grossman, President and Chief Executive Officer. “This is an exciting time for the Company and for immune compromised patients with PIDD. RI-002 was developed to provide a polyclonal immune globulin alternative for clinicians when making a determination on how to care for these chronically ill patients and tailor treatment regimens that specific patients deserve and require. RI-002’s pivotal Phase III clinical trial successfully met its primary and secondary endpoints. We believe RI-002, if approved, will have the ability to provide meaningful outcomes for patients.”

 

The FDA typically provides companies with a notification of BLA acceptance within sixty (“60”) days of submission, and ADMA anticipates that the agency will set a Prescription Drug User Fee Act (“PDUFA”) target action date for RI-002 at that time.

 

About RI-002

ADMA's lead portfolio product candidate, RI-002, which has demonstrated positive Phase III pivotal clinical trial data, is a specialty plasma-derived, polyclonal, intravenous immune globulin (“IVIG”) derived from human plasma containing naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type B, cytomegalovirus (“CMV”), measles, tetanus, etc.) as well as plasma from donors tested to have high levels of neutralizing antibodies to respiratory syncytial virus (“RSV”). ADMA is pursuing an indication for the use of this specialty polyclonal IVIG product for treatment of patients diagnosed with PIDD. Polyclonal antibodies are the primary active component of IVIG products. Polyclonal antibodies are proteins that are used by the body's immune system to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. Data review which has been published in peer reviewed journals indicates that the polyclonal antibodies present in RI-002 support its ability to prevent infections in immune-compromised patients. This data and other information about RI-002 or ADMA Biologics products can be found on the Company website at: www.admabiologics.com/therapies and www.admabiologics.com. RI-002 is protected by U.S. Patents: 9,107,906, 9,714,283, 9,815,886 and 9,969,793, the latter of which affords the Company patent exclusivity for the use of an immune globulin as a prevention and/or treatment for any type of respiratory infection.

 

 

About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease (“PIDD”) and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for other medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886 and 9,969,793 related to certain aspects of its lead product candidate, RI-002. For more information, please visit www.admabiologics.com.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. ("we“, “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," “project,” "intend," “forecast,” "target,” ”anticipate,” “plan,” “planning,” “expect,” “believe,” “will," “is likely,” “will likely,” “should,” “could,” "would," "may," or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements concerning our plans to develop, manufacture, market, launch and expand our own commercial infrastructure and commercialize our current products and future products, the safety, efficacy and expected timing of, and our ability to, obtain and maintain regulatory approvals of our current products and product candidates, and the labeling or nature of any such approvals, the success of our work with our third party vendors and the U.S. Food and Drug Administration (the “FDA”) in furtherance of and progress towards an approval of our Biologics License Application for specialty plasma-based biologics and the ability of such third parties to respond adequately or in a timely manner to the issues raised by the FDA, our ability to successfully pursue commercialization and prelaunch activities, the timeframe within which we may receive approval from the FDA for specialty plasma-based biologics, if at all, the potential of our specialty plasma-based biologics to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease or other indications and our ability to realize increased prices for plasma growth in the plasma collection industry. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

 

COMPANY CONTACT:

Brian Lenz

Executive Vice President and Chief Financial Officer |201-478-5552 | www.admabiologics.com

 

INVESTOR RELATIONS CONTACT:

Jeremy Feffer

Managing Director, LifeSci Advisors, LLC | 917-749-1494 |

 

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg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end